Lack of Research in Graves’ Disease Therapeutics Area

Tuesday 13 March 2012, Amsterdam

The industry analysis specialist, has released its new report, “Graves’ Disease Therapeutics - Pipeline Assessment and Market Forecast to 2019”. The report is an essential source of information and analysis on the global graves disease market. The report identifies the key trends shaping and driving the global Graves’ disease market and provides insight into the current competitive landscape and emerging companies expected to significantly alter the positions of current market leaders. Most importantly, the report provides valuable insights on pipeline products within the global Graves’ disease market.


The Graves’ Disease Therapeutics Market is Forecast to Show Very Slow Growth until 2019

They estimates that the global (the US, the UK, Germany, France, Italy, Spain and Japan) Graves’ disease therapeutics market was worth $169.1m in 2011, expects it to grow at a Compound Annual Growth Rate (CAGR) of 0.9% for the next eight years, to reach $182m by 2019. This very slow growth forecast is primarily attributed to the weak pipeline, coupled with the market being well served by generics. The incidence rate of Graves’ disease is static; therefore only the growing population is contributing to the growth of the market.


Well-Served Market with Low Unmet Need

They estimates that the prevailing market landscape is strong, with generic antithyroid agents and RAI therapy expected to continue to dominate the market during the forecast period. These products offer high efficacy and safety to Graves’ disease patients; as a result, unmet need in the market is low, providing little potential for pipeline drugs to capture market share unless they are disease-modifying in nature and aim at treating the underlying autoimmune condition. However, as the pipeline contains only one disease-modifying drug for Graves’ disease, in the discovery stage of development, the market will continue to be dominated by the existing generic drugs.


Lack of Research in Graves’ Disease Therapeutics Area

The weak pipeline indicates a lack of research in the Graves’ disease therapeutics area. Pharmaceutical companies, research institutes and universities are reluctant to conduct trials in this disease area. As the market is well-served by the currently marketed products the unmet need in the market is low, which indicates a limited scope of revenue generation by any new drugs treating the condition. However, considering the autoimmune nature of the disease, research into developing immunomodulators for the prevention of Graves’ disease in high-risk individuals or for the treatment of Graves’ disease may lead to novel drugs that could change the way the disease is managed.